Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
Moderna (MRNA) closed at $124.06 in the latest trading session, marking a -0.39% move from the prior day.
Benchmarks closed in the positive territory on Tuesday as investors remained optimistic on possible fiscal stimulus and vaccine roll out.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, F, JNJ, MRNA, and GM.
Flat Session Gets Market Back in the Green
KB Home's $1.12 per share was well out in front of the 87 cents in the Zacks consensus, while revenues of $1.19 billion topped the $1.11 billion expected.
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
COVID-19 Vaccine Production to Ramp Up
Guidance for the end of 2020 was to have 20 million Americans with the first half of the two-injection immunization treatment; as of now, only around 9 million Americans have received the first dose.
Moderna (MRNA) plans to initiate clinical studies on new candidates as potential vaccine for seasonal flu, HIV and the Nipah virus.
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Jose M. Vega, M.D. joined Moderna as Chief Safety Officer effective...
Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Uber Technologies, Inc. (NYSE: UBER), the world's leading ridesharing and delivery platform,...
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized...
Bank ETFs should stay strong in the coming days on the back of cheaper valuation, Fed's signal for buybacks, Democrat's control over Senate and spike in bond yields.
Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day
Futures Down as Investors Weigh Covid-19 Cases Against Vaccines
This past Friday brought the U.S. its largest single-day amount of Covid-19 cases since the pandemic began in earnest back in March of last year: 310K in a single 24-hour period.
Health authorities across Canada are warning that they’re running low on COVID-19 vaccines. The ...
--HIV vaccine program to accelerate human validation of novel vaccination strategies
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIDU, MRNA, MU, RIOT, and NEWR.